Market Cap 3.87B
Revenue (ttm) 0.00
Net Income (ttm) -359.64M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,180,600
Avg Vol 2,387,890
Day's Range N/A - N/A
Shares Out 116.65M
Stochastic %K 34%
Beta 0.69
Analysts Strong Sell
Price Target $88.28

Company Profile

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 704 4660
Address:
9920 Pacific Heights Boulevard, Suite 350, San Diego, United States
DG20
DG20 Aug. 17 at 4:29 AM
$NVO $PFE $VKTX GLP + Amylin increases ☝️side effects. GLP + GIP decreases👇 side effects. Sema 7.2 + Cagrilinitide will produce a worse side effect profile than Cagrisema AND Bourla projects excitement, facts be damned… Facts 👇👇👇👇👇
0 · Reply
biolover
biolover Aug. 17 at 3:33 AM
$VKTX $PFE Bourla just in June at GS was talking about “ very high level of weight reduction” and Chris in Aug is saying don’t look at efficacy, this is just to define the dose for 900 pts study .. Which one to believe 😂? And $NVO is running sema 7.2 mg combo with cagrilintide 😂 $LLY is facing fierce competition and “ crowded sector “ 😂
0 · Reply
AlgoFolks
AlgoFolks Aug. 17 at 2:48 AM
$VKTX will be closing my sndk position tomorrow which i bought a lot when it hit 1400. Guess where that money will go next (profit only)
0 · Reply
DG20
DG20 Aug. 17 at 1:22 AM
$VKTX $NVO “IF” NVO ever pursues VKTX they could easily submit an IND for VK2735 + Cagrilinitide which could get an expedited approval in approx 3 years. This would give them a likely best in industry triple agonist and combination patents until nearly 2050. GIP is necessary to improve the GI side effects of GLPs plus it improves WL, MASH and A1C. Maintenance is very important and 21 week data will likely provide ~ 70% of terminal weight loss for VK2735. I suspect we get over 17% which is better weight-loss than Semaglutide 2.4mg in < 1/3rd of the time…
0 · Reply
Stockman824
Stockman824 Aug. 16 at 6:23 PM
$VKTX we could also get a partnership short term and after Phase 3 data a BO from the same company
1 · Reply
Makingmillions192
Makingmillions192 Aug. 16 at 4:32 PM
$LEXX 🚨 MONTHLY CHART: THE MACD CROSS IS HERE! 🚨 Looking at this 1M chart, the multi-year downtrend has officially exhausted, and the structural bottom is IN. MACD Flip: MACD histogram just turned green above 0.00 with the signal lines curling upwards for a textbook bullish crossover—the exact technical setup that preceded the massive 2024 run to $60+. RSI Rebound: RSI printed a higher low near ~38 and is curling up towards 40+, showing steady momentum accumulation. Volume Baseline: Selling volume has completely dried up post-split, leaving a paper-thin float (~1.65M shares). The Spark for the Rally: This technical reversal isn't happening in a vacuum. With commercial validation rolling in (PegBio MTA + PharmaCO deals) and Human Study #7 top-line semaglutide data reading out next, fundamental execution is aligning directly with the chart. If top-line PK data beats Wegovy, this ultra-low float triggers real long-term price discovery. 🚀📈 $RANI $VKTX $LLY $NVO #GLP1
0 · Reply
MonkMan
MonkMan Aug. 16 at 4:24 PM
$VKTX still waiting on some news that favorably shocks the world!
0 · Reply
Vanhalen19845150
Vanhalen19845150 Aug. 16 at 4:16 PM
$VKTX Now bible quotes? Come on Brian put me out of my misery; I’d do it for you can you do it for me? Frustrated Incorporated for 2.5 years now make it happen
0 · Reply
BigB100
BigB100 Aug. 16 at 2:41 PM
$VKTX I feel it’s coming and it’s going to be bigger than any Viking Bull can imagine. They are all lining up , the usual suspects , Amgen , Novo , JNJ and Sanofi in the lead but others are there
2 · Reply
biolover
biolover Aug. 16 at 2:12 PM
$VKTX Doustdar relies on a number of MDs who prescribed ozempic for diabetes years ago and don’t have energy or basic knowledge to switch their pts to a clearly better drug. 0.5 drop in HbA1C makes a difference on life expectancy. That is the sad reality of the health system. Most of $NVO revenues come from ozempic mainly in USA. But will change in 2027
3 · Reply
Latest News on VKTX
Viking Therapeutics Slides: Corporate presentation

Aug 5, 2026, 9:00 AM EDT - 11 days ago

Viking Therapeutics Slides: Corporate presentation


Viking Therapeutics files automatic mixed securities shelf

2026-07-30T10:15:48.000Z - 17 days ago

Viking Therapeutics files automatic mixed securities shelf


Viking Therapeutics Earnings Call Transcript: Q2 2026

Jul 29, 2026, 4:30 PM EDT - 18 days ago

Viking Therapeutics Earnings Call Transcript: Q2 2026


Viking Therapeutics Earnings release: Q2 2026

Jul 29, 2026, 4:30 PM EDT - 18 days ago

Viking Therapeutics Earnings release: Q2 2026


Viking Therapeutics Quarterly report: Q2 2026

Jul 29, 2026, 4:30 PM EDT - 18 days ago

Viking Therapeutics Quarterly report: Q2 2026


Viking Therapeutics Slides: Corporate presentation

Jul 14, 2026, 8:00 AM EDT - 4 weeks ago

Viking Therapeutics Slides: Corporate presentation


Viking Therapeutics management to meet with B. Riley

2026-06-15T16:23:17.000Z - 2 months ago

Viking Therapeutics management to meet with B. Riley


Viking Therapeutics Slides: Corporate presentation

Jun 7, 2026, 7:00 AM EDT - 2 months ago

Viking Therapeutics Slides: Corporate presentation


Viking Therapeutics initiated with a Buy at Lake Street

2026-05-28T13:23:51.000Z - 2 months ago

Viking Therapeutics initiated with a Buy at Lake Street


Viking Therapeutics assumed with a Buy at Truist

2026-05-27T15:22:10.000Z - 2 months ago

Viking Therapeutics assumed with a Buy at Truist


Viking Therapeutics Earnings Call Transcript: Q1 2026

Apr 29, 2026, 4:30 PM EDT - 3 months ago

Viking Therapeutics Earnings Call Transcript: Q1 2026


Viking Therapeutics Earnings release: Q1 2026

Apr 29, 2026, 4:30 PM EDT - 3 months ago

Viking Therapeutics Earnings release: Q1 2026


Viking Therapeutics Quarterly report: Q1 2026

Apr 29, 2026, 4:30 PM EDT - 3 months ago

Viking Therapeutics Quarterly report: Q1 2026


Viking Therapeutics Proxy statement: Proxy filing

Apr 1, 2026, 8:00 AM EDT - 4 months ago

Viking Therapeutics Proxy statement: Proxy filing


Viking Therapeutics Proxy statement: Proxy filing

Apr 1, 2026, 8:00 AM EDT - 4 months ago

Viking Therapeutics Proxy statement: Proxy filing


Viking Therapeutics Slides: Corporate presentation

Mar 13, 2026, 7:00 AM EDT - 5 months ago

Viking Therapeutics Slides: Corporate presentation


Viking Therapeutics Earnings Call Transcript: Q4 2025

Feb 11, 2026, 4:30 PM EST - 6 months ago

Viking Therapeutics Earnings Call Transcript: Q4 2025


Viking Therapeutics Annual report: Q4 2025

Feb 11, 2026, 4:30 PM EST - 6 months ago

Viking Therapeutics Annual report: Q4 2025


Viking Therapeutics Earnings release: Q4 2025

Feb 11, 2026, 4:30 PM EST - 6 months ago

Viking Therapeutics Earnings release: Q4 2025


Viking Therapeutics Slides: Corporate presentation

Jan 14, 2026, 7:00 AM EST - 7 months ago

Viking Therapeutics Slides: Corporate presentation


Viking Therapeutics Slides: Corporate presentation

Dec 9, 2025, 7:00 AM EST - 8 months ago

Viking Therapeutics Slides: Corporate presentation


Viking Therapeutics Slides: Corporate Presentation

Nov 19, 2025, 7:00 AM EST - 9 months ago

Viking Therapeutics Slides: Corporate Presentation


Viking Therapeutics Earnings Call Transcript: Q3 2025

Oct 22, 2025, 4:30 PM EDT - 10 months ago

Viking Therapeutics Earnings Call Transcript: Q3 2025


Viking Therapeutics Quarterly report: Q3 2025

Oct 22, 2025, 4:30 PM EDT - 10 months ago

Viking Therapeutics Quarterly report: Q3 2025


Viking Therapeutics Earnings release: Q3 2025

Oct 22, 2025, 4:30 PM EDT - 10 months ago

Viking Therapeutics Earnings release: Q3 2025


Viking Therapeutics Slides: Corporate Presentation

Oct 1, 2025, 7:00 AM EDT - 11 months ago

Viking Therapeutics Slides: Corporate Presentation


Viking Therapeutics: What's Happening With VKTX Stock?

Aug 20, 2025, 9:50 AM EDT - 1 year ago

Viking Therapeutics: What's Happening With VKTX Stock?


Viking Therapeutics Transcript: Study Result

Aug 19, 2025, 8:00 AM EDT - 1 year ago

Viking Therapeutics Transcript: Study Result


Viking Therapeutics Press release: Study Result

Aug 19, 2025, 8:00 AM EDT - 1 year ago

Viking Therapeutics Press release: Study Result


Viking Therapeutics Earnings Call Transcript: Q2 2025

Jul 23, 2025, 4:30 PM EDT - 1 year ago

Viking Therapeutics Earnings Call Transcript: Q2 2025


Viking Therapeutics Quarterly report: Q2 2025

Jul 23, 2025, 4:30 PM EDT - 1 year ago

Viking Therapeutics Quarterly report: Q2 2025


Viking Therapeutics Earnings release: Q2 2025

Jul 23, 2025, 4:30 PM EDT - 1 year ago

Viking Therapeutics Earnings release: Q2 2025


Viking Therapeutics Slides: Corporate Presentation

Jul 3, 2025, 7:00 AM EDT - 1 year ago

Viking Therapeutics Slides: Corporate Presentation


Viking Therapeutics Slides: Corporate Presentation

Jun 14, 2025, 7:00 AM EDT - 1 year ago

Viking Therapeutics Slides: Corporate Presentation


Viking Therapeutics Slides: Company Presentation

May 2, 2025, 7:00 AM EDT - 1 year ago

Viking Therapeutics Slides: Company Presentation


Viking Therapeutics Earnings Call Transcript: Q1 2025

Apr 23, 2025, 4:30 PM EDT - 1 year ago

Viking Therapeutics Earnings Call Transcript: Q1 2025


Viking Therapeutics Quarterly report: Q1 2025

Apr 23, 2025, 4:30 PM EDT - 1 year ago

Viking Therapeutics Quarterly report: Q1 2025


Viking Therapeutics Earnings release: Q1 2025

Apr 23, 2025, 4:30 PM EDT - 1 year ago

Viking Therapeutics Earnings release: Q1 2025


Viking Therapeutics Proxy statement: Proxy Filing

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Viking Therapeutics Proxy statement: Proxy Filing


Viking Therapeutics Proxy statement: Proxy Filing

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Viking Therapeutics Proxy statement: Proxy Filing


Viking Therapeutics Proxy statement: Proxy Filing

Apr 8, 2025, 8:00 AM EDT - 1 year ago

Viking Therapeutics Proxy statement: Proxy Filing


Viking Therapeutics Proxy statement: Proxy Filing

Apr 8, 2025, 8:00 AM EDT - 1 year ago

Viking Therapeutics Proxy statement: Proxy Filing


DG20
DG20 Aug. 17 at 4:29 AM
$NVO $PFE $VKTX GLP + Amylin increases ☝️side effects. GLP + GIP decreases👇 side effects. Sema 7.2 + Cagrilinitide will produce a worse side effect profile than Cagrisema AND Bourla projects excitement, facts be damned… Facts 👇👇👇👇👇
0 · Reply
biolover
biolover Aug. 17 at 3:33 AM
$VKTX $PFE Bourla just in June at GS was talking about “ very high level of weight reduction” and Chris in Aug is saying don’t look at efficacy, this is just to define the dose for 900 pts study .. Which one to believe 😂? And $NVO is running sema 7.2 mg combo with cagrilintide 😂 $LLY is facing fierce competition and “ crowded sector “ 😂
0 · Reply
AlgoFolks
AlgoFolks Aug. 17 at 2:48 AM
$VKTX will be closing my sndk position tomorrow which i bought a lot when it hit 1400. Guess where that money will go next (profit only)
0 · Reply
DG20
DG20 Aug. 17 at 1:22 AM
$VKTX $NVO “IF” NVO ever pursues VKTX they could easily submit an IND for VK2735 + Cagrilinitide which could get an expedited approval in approx 3 years. This would give them a likely best in industry triple agonist and combination patents until nearly 2050. GIP is necessary to improve the GI side effects of GLPs plus it improves WL, MASH and A1C. Maintenance is very important and 21 week data will likely provide ~ 70% of terminal weight loss for VK2735. I suspect we get over 17% which is better weight-loss than Semaglutide 2.4mg in < 1/3rd of the time…
0 · Reply
Stockman824
Stockman824 Aug. 16 at 6:23 PM
$VKTX we could also get a partnership short term and after Phase 3 data a BO from the same company
1 · Reply
Makingmillions192
Makingmillions192 Aug. 16 at 4:32 PM
$LEXX 🚨 MONTHLY CHART: THE MACD CROSS IS HERE! 🚨 Looking at this 1M chart, the multi-year downtrend has officially exhausted, and the structural bottom is IN. MACD Flip: MACD histogram just turned green above 0.00 with the signal lines curling upwards for a textbook bullish crossover—the exact technical setup that preceded the massive 2024 run to $60+. RSI Rebound: RSI printed a higher low near ~38 and is curling up towards 40+, showing steady momentum accumulation. Volume Baseline: Selling volume has completely dried up post-split, leaving a paper-thin float (~1.65M shares). The Spark for the Rally: This technical reversal isn't happening in a vacuum. With commercial validation rolling in (PegBio MTA + PharmaCO deals) and Human Study #7 top-line semaglutide data reading out next, fundamental execution is aligning directly with the chart. If top-line PK data beats Wegovy, this ultra-low float triggers real long-term price discovery. 🚀📈 $RANI $VKTX $LLY $NVO #GLP1
0 · Reply
MonkMan
MonkMan Aug. 16 at 4:24 PM
$VKTX still waiting on some news that favorably shocks the world!
0 · Reply
Vanhalen19845150
Vanhalen19845150 Aug. 16 at 4:16 PM
$VKTX Now bible quotes? Come on Brian put me out of my misery; I’d do it for you can you do it for me? Frustrated Incorporated for 2.5 years now make it happen
0 · Reply
BigB100
BigB100 Aug. 16 at 2:41 PM
$VKTX I feel it’s coming and it’s going to be bigger than any Viking Bull can imagine. They are all lining up , the usual suspects , Amgen , Novo , JNJ and Sanofi in the lead but others are there
2 · Reply
biolover
biolover Aug. 16 at 2:12 PM
$VKTX Doustdar relies on a number of MDs who prescribed ozempic for diabetes years ago and don’t have energy or basic knowledge to switch their pts to a clearly better drug. 0.5 drop in HbA1C makes a difference on life expectancy. That is the sad reality of the health system. Most of $NVO revenues come from ozempic mainly in USA. But will change in 2027
3 · Reply
Frisbee_DNA
Frisbee_DNA Aug. 16 at 8:24 AM
$VKTX $SRPT I can say with great experience that holding these two stocks have required the patience & anguish of Job. The phrase "the patience of Job" comes from James 5:11 in the New Testament. It describes someone who stays strong and keeps their faith through extreme and long-lasting pain. Opinions on Reddit are mixed regarding whether Job was truly "patient". While many people use the term to mean sitting quietly without complaint, the actual biblical story shows Job crying out in anguish, questioning God, and even cursing the day he was born.
0 · Reply
Joel43
Joel43 Aug. 16 at 7:30 AM
$VKTX if doustbar means that when GLP1s with superior efficacy and safety profile takes over 90% of obesity market while Novo pathetic pipeline can still retain single digit market is an argument against winner takes all (Novo will still have <10% market share so..), yes he is right
0 · Reply
whiskyqueen
whiskyqueen Aug. 16 at 6:04 AM
1 · Reply
VentureBack
VentureBack Aug. 15 at 8:43 PM
0 · Reply
Freakyguy666
Freakyguy666 Aug. 15 at 7:43 PM
$VKTX the problem with these MODELS is that they are “MODELS” and do NOT account for the REAL WORLD where the BASELINE PLACEBO is CHANGING due to a variety of factors such as previous GLP-1 use and expectations of Nausea from prior experience & exposure to others who have had negative reactions to similar drugs. THIS UNKNOWN will have a HUGE effect not only on Tolerability but also EFFICACY as it is much more likely today than when those models were first created that those on Placebo will have higher weightloss than those in similar trials from years past where these drugs & their effects were still relatively unknown. Bottomline: these Models are structurally BROKEN as they do NOT account for the changing Baseline of Placebo—which is what the actual Benefits/Efficacy will be compared to!
5 · Reply
Freakyguy666
Freakyguy666 Aug. 15 at 7:30 PM
$VKTX keep you $100 for lunch money. You’ll need it😆
0 · Reply
biolover
biolover Aug. 15 at 3:55 PM
$VKTX this is interesting as Reta 2 and 4 mg doses largely follow TZP .. and then deeper wt loss above 6 mg dose .. there is descent chance VK will beat Reta till 16 wks then Reta catch up later. Although unclear how much 1.25 mg dose to slow initial wt loss .. but good idea to mitigate nausea. Descent chance Vk will beat Reta at 21 wks. Reta got 17.4% at 24 wks as I recall in $LLY phase 2 with rapid 4-8 mg escalation. Just pts continue to lose wt on Reta long term and many don’t feel well. May be the GLP1 and glucagon kicking in at top doses. While early on GIP dominates
0 · Reply
Wal187
Wal187 Aug. 15 at 3:13 PM
$VKTX I'm sure at this point everyone knows somebody on either reta or tirz. It seems like everyone I talk to the medication stops working around the 6 month mark. A lot of them are on the 15mg of tirz and haven't lost weight in months. Once more competition is on the market it seems like these medications will constantly be rotated by users trying to regain the wl momentum
1 · Reply
Domo06
Domo06 Aug. 15 at 10:57 AM
$VKTX all in!
0 · Reply
Dazedconfused12
Dazedconfused12 Aug. 15 at 10:22 AM
0 · Reply
Twitgb
Twitgb Aug. 15 at 10:02 AM
$VKTX hmmmm
1 · Reply
PeteMitchell1981
PeteMitchell1981 Aug. 15 at 9:46 AM
$VKTX getting dry powder ready.
1 · Reply